Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-04-24
2007-04-24
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
10987990
ABSTRACT:
Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.
REFERENCES:
patent: 5801145 (1998-09-01), Gariepy et al.
patent: 5968894 (1999-10-01), Lingwood et al.
patent: 6228370 (2001-05-01), Lingwood et al.
patent: 6835710 (2004-12-01), Lingwood et al.
Kiarash et al. Apr. 15, 1994; Glycosphingolipid receptor function is modified by fatty acid content: Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. J. Biol. Chem. 269(15): 11138-11146.
Mangeney et al. 1993; Apoptosis induced in Burkitt's Llymphoma ceels via Gb3/CD77, a glycolipid antigen. Cancer Res. 53(21): 5314-5319.
Farkas-Himsley, et al: “Bacterial Proteinaceous Products (Bacteriocins) as Cytotoxic Agents of Neoplasia”,Cancer Research, vol. 36, pp. 3562-3567 (Oct. 1976).
Hill, et al: “Further studies of the Action of a Partially Purified Bacteriocin against a Murine Fibrosarcoma”,Cancer Research, vol. 51, pp. 1359-1365 (Mar. 1, 1991).
Karmali: “Infection by Verocytotoxin-ProducingEscherichia coli”, Clinical Microbiology Reviews, vol. 2, No. 1, pp. 15-38 (Jan. 1989).
Riley, et al: “Hemorrhagic Colitis Associated with a RareEscherichia coliSerotype”,The New England Journal of Medicine, vol. 308, No. 12, pp. 681-685 (Mar. 24, 1983).
Lingwood: “Verotoxin and Their Glycolipid Receptors”,Advances in Lipid Research, vol. 25, pp. 189-211 (1993).
van de Kar, et al: Tumor Necrosis Factor and Interleukin-1 Induce Expression of the Verocytotoxin Receptor Globotriaosylceramide on Human Endothelial Cells: Implications.
Obrig, et al: “Endothelial Heterogeneity in Shiga Toxin Receptors and Responses”,The Journal of Biological Chemistry, vol. 268, No. 21, pp. 15484-15488 (Jul. 25, 1993).
Lingwood: “Verotoxin-Binding in Human Renal Sections”,Nephron, vol. 66, pp. 21-28 (1994).
Cohen, et al: “Expression of Glycolipid Receptors to Shiga-like Toxin on Human B Lymphocytes: a Mechanism for the failure of long-lived antibody response to dysenteric disease”,International Immunology, vol. 2, No. 1, pp. 1-8 (1990).
Gregory, et al: “Identification of a Subset of Normal B Cells with a Burkitt's Lymphoma (BL)-Like Phenotype”,The Journal of Immunology, vol. 139, No. 1, pp. 313-318 (Jul. 1, 1987).
Maloney, et al: “CD19 has a Potential CD77 (Globotriaosyl Ceramide)-binding Site with Sequence Similiarity to Verotoxin B-subunits: Implications of Molecular Mimicry for B Cell Adhesion and EnterohemorrhagicEscherichia coliPathogenesis”,J. Exp. Med., vol. 180, pp. 191-201 (Jul. 1994).
Maloney, et al: “Interaction of Verotoxins with Glycosphingolipids”,Trends in Glycoscience and Glycotechnology, vol. 5, No. 21, pp. 23-31 (Jan. 1993).
Li, et al: “Accumulation of Globotriaosylceramide in a case of Leiomyosarcoma”,Biochemistry J., vol. 240, pp. 925-927 (1986).
Mannori, et al: Role of Glycolipids in the Metastatic Process: Characteristics of Neutral Glycolipids in Clones with Different Metastatic Potentials Isolated from a Murine Fibrosarcoma.
Ohyama, et al: “Changes in Glycolipid Expression in Human Testicular Tumor”,Intl. J. Cancer, vol. 45, pp. 1040-1044 (1990).
Naiki, et al: “Human Erythrocyte P and PkBlood Group Antigens: Identification as Glycosphingolipids”,Biochemical and Biophysical Research Communications, vol. 60, No. 3, pp. 1105-1111 (1974).
Pallesen, et al: “Distribution of the Burkitt's Lymphoma-associated Antigen (BLA) in Normal Human Tissue and Malignant Lymphoma as Defined by Immunohistological Staining with Monoclonal Antibody 38.13”,J. Cancer Res. Clin. Oncol., vol. 113, pp. 67-86 (1987).
Kasai, et al: “Tissue Distribution of the PkAntigen as Determined by a Monoclonal Antibody”,Journal of Immunogenetics, vol. 12, pp. 213-220 (1985).
Pudymaitis, et al: “Susceptibility to Verotoxin as a Function of the Cell Cycle”,Journal of Cellular Physiology, vol. 150, pp. 632-639 (1992).
Lingwood, et al: “Glycolipid Modification of a2 Interferon Binding”,Biochem, J., vol. 283, pp. 25-26 (1992).
Sandvig, et al: “Retrograde Transport of Endocytosed Shiga Toxin to the Endoplasmic Reticulum”,Nature, vol. 358, pp. 510-512 (Aug. 6, 1992).
Mangeney, et al: “Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen”,Cancer Res., vol. 53, pp. 5314-5319 (1993).
Costello, et al. “Human cerebral endothelium; Isolation and characterization of cell derived from microvessels of non-neoplastic and malignant glial tissue”J. Neuro Oncol., vol. 8, pp. 231-243 (1990).
Pintus, et al. “Endothelial cell growth supplement: a cell cloning factor that promotes the growth of mono-clonal antibody producing hydridoma cells”,J. Immunological Methods, vol. 61, pp. 195-200 (1983).
Rutka, et al. “Characterization of normal human brain cultures: Evidence for the outgrowth of leptomeningeal cells”,Laboratory Investigation; vol. 55, pp. 71-85 (1986).
Sandvig et al. “Toxin Induced Cell Lysis: Protection by 3-Methyladenine and Cycloheximide”EXP CELL, vol. 200, pp. 253-262 (1992).
Head, et al.: “Purification and characterization of verocytotoxin 2”,FEMS Microbiology Letters, 51, pp. 211-216 (1988).
Ramotar, et al. “Characterization of Shiga-like toxin l B subunit purified from overproducing clones of the SLT-l B cistron”,Biochem. J., vol. 272, pp. 805-811 (1990).
Geva, legal representative Ruth
Hill Richard
Kroyanker, legal representative Leorah
Lingwood Clifford A.
Carlson Karen Cochrane
DeConti, Jr. Giulio A.
HSC Research and Development Limited Partnership
Lahive & Cockfield LLP
Ontario Cancer Institute
LandOfFree
Verotoxin pharmaceutical compositions and medical treatments... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Verotoxin pharmaceutical compositions and medical treatments..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Verotoxin pharmaceutical compositions and medical treatments... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3745809